Description
At previous Member May and National Conference sessions, we explored the evolving field of Limb Loss, Difference, and Preservation Rehabilitation (LDPR). This session will continue that conversation by focusing on what excellence looks like in LDPR care, specifically, what defines a LDPR Center of Excellence and how collaboration across centers can strengthen the field. This will be an interactive session. Panelists will provide brief insights and help guide the discussion with the audience around three main themes: 1. What makes a program a true Center of Excellence 2. Key elements across clinical care, education, service, and research 3. Perspectives on developing a more connected network of LDPR centers The goal is to generate shared ideas, identify areas of alignment and variation, and explore practical next steps for advancing coordinated LDPR systems of care.
Learning Objectives
After completing this live activity, the participant should be able to:
- Describe the defining characteristics of a LDPR Center of Excellence
- Identify essential clinical, education, service, and research elements that support high-quality LDPR care
- Discuss the opportunities and challenges involved in developing a connected LDPR network
Accreditation Statement
The American Academy of Physical Medicine and Rehabilitation (AAPM&R) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Credit Designation
The American Academy of Physical Medicine and Rehabilitation (AAPM&R) designates this live activityfor a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Statement
In accordance with ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, AAPM&R requires all individuals who are in a position to affect the strategic direction of AAPM&R and/or control the content of an educational activity to disclose all financial relationships with any ineligible company within the last 24 months. The ACCME defines an “ineligible company” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Disclosures are made in written form prior to the start of the educational activity, and any potential conflicts of interest that exist are mitigated prior to the start of the activity through AAPM&R’s Conflict of Interest Disclosure and Resolution Policy Process. Individuals in a position to affect the strategic direction of AAPM&R and/or control content and their disclosed financial relationships are listed below.
No other planners, faculty, or individuals in control of content disclosed any relevant financial relationships.
Principle Faculty
Name, Credential(s): Company Name, Nature of financial relationship;
Prateek Grover MBBS PhD MHA FAAPMR - Nothing to disclose
Joseph Burris MD, FAAPMR - Nothing to disclose
Marlis Gonzalez Fernandez MD, PhD, FAAPMR - Nothing to disclose
David Crandell MD, FAAPMR - Nothing to disclose
Vinay Vanodia MD, Director of Limb Loss - Nothing to disclose
AAPM&R Medical Education Committee
Name, Credential(s): Company Name, Nature of financial relationship
Rachel Brakke Holman, MD - Nothing to Disclose
Sarah M. Eickmeyer, MD - Nothing to Disclose
Chelsea D. Frost, MD, MS - Nothing to Disclose
David J. Haustein, MBA,MD,MBA - Relationships to Disclose
Sarah K. Hwang, MD - Nothing to Disclose
Ravi E. Kasi, MD - Nothing to Disclose
Caroline Pupke, DO - Nothing to Disclose
Monica E. Rho, MD - Nothing to Disclose
McCasey R. Smith, MD - Nothing to Disclose
Jennifer A. Soo Hoo, MD - Nothing to Disclose
Brionn K. Tonkin, MD - Nothing to Disclose
Stephanie Tow, MD - Nothing to Disclose
Justin L. Weppner, DO - Nothing to Disclose
Alexandra G. Wolfe, DO - Nothing to Disclose
FDA Disclosures
All faculty members for this activity have disclosed they do not intend to discuss or demonstrate any pharmaceutical or medical device for which FDA clearance has not been approved.